You have not mentioned what type of seizure you have. The New Generation of GABA Enhancers: Potential in the Treatment of Epilepsy. In recent years 4 new anticonvulsants, namely vigabatrin, tiagabine, gabapentin and topiramate, with a mechanism of action considered to be primarily via an effect on GABA, have been licensed. Vigabatrin elevates brain GABA levels by inhibiting the enzyme GABA transaminase which is responsible for intracellular GABA catabolism. In contrast, tiagabine elevates synaptic GABA levels by inhibiting the GABA uptake transporter, GAT1, and preventing the uptake of GABA into neurons and glia. Gabapentin, a cyclic analogue of GABA, acts by enhancing GABA synthesis and also by decreasing neuronal calcium influx via a specific subunit of voltage-dependent calcium channels. Topiramate acts, in part, via an action on a novel site of the GABAA receptor. Although these drugs are useful in some patients, overall, they have proven to be disappointing as they have had little impact on the prognosis of patients with intractable epilepsy. Retigabine is an example of a new antiepileptic drug that has been tested in clinical trials. Surgical methods like Resective Surgery, Multiple Subpial Transections, Vagus Nerve Stimulation, Deep Brain Stimulation. RNS (Responsive Neurostimulator System and DBS (Deep Brain Stimulation) could offer new, potential treatment for patents with epilepsy without a lot of other treatment options, especially those whose seizures aren't controlled by drugs and who aren't good surgical candidates. Patients who have epileptic seizures after using one drug tend to continue to have them on another.